Sotalol



Sotalol
Systematic (IUPAC) name
N-[4-(1-hydroxy-2-isopropylamino-
ethyl)-phenyl]-methanesulfonamide
Identifiers
CAS number 3930-20-9
ATC code C07AA07
PubChem 5253
Chemical data
S 
Mol. mass 272.3624 g/mol
Pharmacokinetic data
Bioavailability >95%
Metabolism Not metabolised
Half life 12 hours
Excretion Renal
Lactic (In lactating females)
Therapeutic considerations
Pregnancy cat.

B(US)

Legal status

℞ Prescription only

Routes oral

Sotalol (trade names Betapace and Betapace AF, Berlex Laboratories) is a drug used in individuals with rhythm disturbances (cardiac arrhythmias) of the heart, and to treat hypertension in some individuals.

Pharmacology

It falls into the class III beta blocker because of its primary action on the β-adrenergic receptors in the heart.

By blocking the potassium channels, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity.

It also slows atrioventricular (AV) nodal conduction (beta-blocking effect).

Sotalol is a enantiomers. The L isomer is a beta blocker.

Sotalol is not selected for its beta-blocking ability, but rather for its Class III (potassium blocking) properties.

Indications

Sotalol is used to treat ventricular tachycardias as well as atrial fibrillation. Betapace AF is specifically labeled for atrial fibrillation.

Some evidence suggests that sotalol should be avoided in the setting of decreased ejection fraction due to heart attack.[1]

See also

v • d • e
Labetalol
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sotalol". A list of authors is available in Wikipedia.